- Kidney Cancer Journal is the only peer-reviewed medical journal and most comprehensive source of scientific information focusing exclusively on renal cell carcinoma
- Robert A. Figlin, MD, FACP , Editor-in-Chief. Principal investigator on numerous kidney cancer clinical trials. Dr. Figlin, MD is the Associate Director of the Academic Development Program and Director of the Division of Hematology/Oncology at Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute. He is board-certified in both medical oncology and internal medicine.
- Dr. Senthil Samy, PhD
Executive Editor and Publisher.
sen'at'kidney-cancer-journal.com| Phone: +1 (919) 694-3599
- Published quarterly since 2003
- Distributed as a complimentary professional service to approximately 12,300 physicians, including all medical oncologists and targeted urologists.
- Utilizes a Medical Advisory Board and Editorial Advisory Board of more than 30 physicians who are leading investigators in this field.
- Archives available through the KCA’s website at www.kidneycancer.org
- Special Reports and supplements covering ASCO and highlights from the annual International Kidney Cancer Association Meeting
* Program pricing available upon request
- For Sponsored contents and clinical strategies: Contact: sen'at'kidney-cancer-journal.com
Patient Outreach, Engagement, Advocacy, and Support
The Kidney Cancer Association (KCA) is a charitable organization made up of patients, family members, physicians, researchers, and other health professionals. We fund, promote, and collaborate with the National Cancer Institute (NCI), American Society for Clinical Oncology (ASCO), American Urologic Association (AUA), and other institutions on research projects. They educate families and physicians, and serve as an advocate on behalf of patients at the state and federal levels.
The Kidney Cancer Association was founded in 1990 by a small group of patients, including Eugene P. Schonfeld, Ph.D., and medical doctors in Chicago, Illinois. It is a nonprofit charity incorporated in the State of Illinois. It has also been designated as a tax exempt organization under Section 501(c)(3) of the U.S. Internal Revenue Service code. Donations to the Association are tax deductible.
The Kidney Cancer Association is a member of, and is certified by, the National Health Council as an organization in full compliance with the Standards of Excellence for voluntary health agencies.
The Kidney Cancer Association is developing a global presence and is creating websites in several languages, including Chinese, Japanese, Spanish, German, French, Italian and other languages. New patient support groups are planned for the European Union, Asia and Australia in 2007.
Connect with Oncology and Urology Professionals
Digital, Print, Multi-Media, Special Projects
KCJ Digital Solutions Programs
For specific information on these programs contact: Susan Hirschhaut Director of Advertising and Strategic Initiatives susan'at'kidney-cancer-journal.com (847) 476-0588
Circulation TOTAL = 12,300 Physicians
|Medical Oncologists||Hem / Oncologists||Oncologist TKI prescribers||Urologists||Other Oncologists|
This breakdown is targeted base on ICD10 codes for physicians with a focus on kidney cancer (List provided by DMD/Direct Medical Data, LLC.)
|Full Page (B&W)||8,500||8,300||8,200||8,000||7,800||7,700|
|1/2 Page (B&W)||6,800||6,600||6,350||5,000||5,700||5,300|
|1/4 Page (B&W)||4,200||4,150||3,900||3,800||3,700||3,500|
2 Color $800
4 Color $1,700
Premium Position – Cover 4
A 50% premium charge will be applied to the B&W Full Page rate. Based on the client’s Frequency Rate.
Premium Position – Cover 2
A 25% premium charge will be applied to the B&W Full Page rate. Based on the client’s Frequency Rate.
Mechanical RequirementsTrim Size: 8 3/8” x 10 7/8”
|Ad Size*||(w x h)||(w x h)||(w x h)||(w x h)|
|Spread||16 1/4” x 10 3/8”||17” x 11 1/8”||16 1/4” x 10 3/8’||16 ¾” x 10 7/8”|
|Full Page||7 7/8” x 10 3/8”||8 5/8” x 11 1/8”||7 7/8” x 10 3/8”||8 3/8” x 10 7/8”|
|1/2 Page Vertical||3 3/4” x 10 3/8”||4 3/8” x 11 1/8”||3 5/8” x 10 3/8”||4 1/8” x 1- 7/8”|
|1/2 Page Horizontal||7 3/4” x 5”||8 5/8” x 5 5/8”||7 3/4” x 4 7/8”||8 3/8” x 5 3/8”|
|1/2 Page Hor. Spr.||16 1/4” x 5”||17” x 5 5/8”||16 1/4” x 4 7/8”||16 3/4” x 5 3/8”|
|1/4 Page||3 3/4” x 5”||4 3/8” x 5 5/8”||3 5/8” x 4 7/8”||4 1/8” x 5 3/8”|
* Other size ads are available upon request.
|Binding Method: Saddle Stitched||Color: 4 Color (CMYK)|
|Bleed: 1/8 “ (8.675” x 11.125”)||Live Area: 7 “ x 10”|
|Maximum Density: 300||Safety: Keep Live Matter from trim – 1/4”|
|Spreads: Live area is 15 1/2” x 10”|
Please send all files as press-quality PDF files, with crop marks, bleeds, and a color proof or matching with final press proofs.
Website Advertising Specifications
- 300 x 250 pixels (medium rectangle)
- 468 x 60 pixels (full banner)
- 728 x 90 pixels (leader board)
- 300 x 600 pixels (half-page skyscraper)
- 300 x 100 pixels (low rectangle)
2024 Issue and Closing Dates
|Volume 22, Number 1:||February - GU ASCO edition
MATERIALS: January 24
|Volume 22, Number 2:|| June
MATERIALS: May 11
|Volume 22, Number 3:|| September
MATERIALS: Aug 28
|Volume 22, Number 4:|| December
For ROB ads, Inserts, Tip-Ons, etc., to be inserted or printed, all materials
can be sent to the attention of:
Susan Hirschhaut Director of Advertising and Strategic Initiatives email@example.com (847) 476-0588
Our advertising policy is consistent with the principles mentioned in the Recommendations on Publication Ethics Policies for Medical Journals which issued by the World Association of Medical Editors (WAME).
- All advertisements and commercially sponsored publications are independent from editorial decisions. Kidney Cancer Journal does not endorse any product or service marked as an advertisement or promoted by a sponsor in Kidney Cancer Journal publications. Editorial content is not compromised by commercial or financial interests, or by any specific arrangements with advertising clients or sponsors.
- Kidney Cancer Journal reserves the right to decline any type of advertising that is damaging to the brand of Kidney Cancer Journal or is inappropriate to the content held on the Kidney Cancer Journal
Advertisements may not be deceptive or misleading, and must be verifiable. Advertisements should clearly identify the advertiser and the product or service being offered. Exaggerated or extravagantly worded copy will not be allowed. Advertisements will not be accepted if they appear to be indecent or offensive in either text or artwork, or if they relate to content of a personal, racial, ethnic, sexual orientation, or religious nature.
Advertising for the following categories is prohibited:
- Weapons, firearms, ammunition
- Gambling and lottery
- Pornography or related themes
- Political and religious advertisements
- Advertisements that claim to have a “miracle” cure or method
- Advertisements that make unsubstantiated health claims for the products advertised
- Advertisements directed at children
Advertising complaints policy
Please send any complaints about advertising to: firstname.lastname@example.org